Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134241 | 1.00 | TSHR (0.46) | TSHRCYP3A4ALDH1A1MAPTCHRNA7 | |
| SCHEMBL1730835 | 1.00 | TSHR (0.46) | TSHRCYP3A4ALDH1A1MAPTCHRNA7 | |
| SCHEMBL28986558 | 1.00 | TSHR (0.46) | TSHRCYP3A4ALDH1A1MAPTCHRNA7 | |
| SCHEMBL1101003 | 0.93 | ALDH1A1 (0.45) | TSHRCYP3A4ALDH1A1MAPTCHRNA7 | |
| SCHEMBL17438169 | 0.87 | TSHR (0.48) | TSHRCYP3A4ALDH1A1TDP1LMNA | |
| SCHEMBL3176056 | 0.81 | ALDH1A1 (0.42) | TSHRALDH1A1MAPTCHRNA7ACHE | |
| SCHEMBL24015469 | 0.80 | TSHR (0.46) | TSHRCYP3A4ALDH1A1TDP1LMNA | |
| SCHEMBL874873 | 0.80 | LMNA (0.62) | TSHRCYP3A4ALDH1A1MAPTCHRNA7 | |
| SCHEMBL3921442 | 0.80 | LMNA (0.62) | TSHRCYP3A4ALDH1A1MAPTCHRNA7 | |
| SCHEMBL4576404 | 0.80 | LMNA (0.62) | TSHRCYP3A4ALDH1A1MAPTCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308105-A1 | NOVEL METHOD FOR PRODUCING HYDROXAMIC ACID DERIVATIVE, AND INTERMEDIATE THEREFOR | FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) | 2020-10-01 | — | — | US | disclosed |
| US-20160097063-A1 | Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-04-07 | — | — | US | disclosed |
| US-20160097063-A1 | Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-04-07 | — | — | US | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | TSHR 3008/4885CYP3A4 269/4885ALDH1A1 943/4885 |
| US-20200308105-A1 | NOVEL METHOD FOR PRODUCING HYDROXAMIC ACID DERIVATIVE, AND INTERMEDIATE THEREFOR | HADH, HDAC11, HADHA | TSHR 3061/4885CYP3A4 1338/4885ALDH1A1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.